XEN 2174

Drug Profile

XEN 2174

Alternative Names: XEN-2174

Latest Information Update: 08 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xenome
  • Class Analgesics; Peptides
  • Mechanism of Action Adrenergic uptake inhibitors; Catecholamine plasma membrane transport protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer pain; Postoperative pain

Most Recent Events

  • 04 Sep 2012 XEN 2174 is still in phase I/II development for Cancer pain
  • 04 Sep 2012 Discontinued - Phase-I for Postoperative pain (in volunteers) in Australia (IV)
  • 01 Aug 2012 Xenome completes a phase II trial in Postoperative pain in Bulgaria (EudraCT2010-019109-40)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top